American Journal of Cardiology
Volume 102, Issue 11 , Pages 1509-1513 , 1 December 2008

Usefulness of Self-Reported Periodontal Disease to Identify Individuals With Elevated Inflammatory Markers at Risk of Cardiovascular Disease

  • Heidi Mochari, MPH, RD

      Affiliations

    • Columbia University Medical Center/New York Presbyterian Hospital, New York, New York
    • ,
  • John T. Grbic, DMD, MMedSc

      Affiliations

    • Columbia University, College of Dental Medicine, New York, New York
    • ,
  • Lori Mosca, MD, MPH, PhD

      Affiliations

    • Columbia University, College of Physicians and Surgeons/New York Presbyterian Hospital, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: 212-305-4866; fax: 212-342-5238

Received 23 May 2008 ,Revised 15 July 2008 ,Accepted 15 July 2008.

References 

  1. Eke PI, Genco RJ. CDC periodontal disease surveillance project: background, objectives, and progress report. J Periodontol. 2007;78:1366–1371
  2. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease epidemiology and possible mechanisms. J Am Dent Assoc. 2002;133:14S–22S
  3. Ridker PM. Inflammation, infection and cardiovascular risk (How good is the clinical evidence?). Circulation. 1998;97:1671–1674
  4. Slade GD. Interim analysis of validity of periodontitis screening questions in the Australian population. J Periodontol. 2007;78:1463–1470
  5. Genco RJ, Falkner KL, Grossi S, Dunford R, Trevisan M. Validity of self-reported measures for surveillance of periodontal disease in two western New York population-based studies. J Periodontol. 2007;78:1439–1454
  6. Boucher B, Cotterchio M, Kreiger N, Nadalin V, Block T, Block G. Validity and reliability of the Block 98 Food-Frequency Questionnaire in a sample of Canadian women. Public Health Nutr. 2006;9:84–93
  7. Nutritionquest. Questionnaires & screeners. http://www.nutritionquest.com/products/questionnaires_screeners.htmAccessed February 6, 2008
  8. United States Department of Agriculture. USDA National Nutrient Database for Standard Reference (Release 20). http://www.ars.usda.gov/services/docs.htm?docid=8964Accessed: February 6, 2008
  9. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: Questionnaires: English versions. http://www.cdc.gov/brfss/questionnaires/english.htmAccessed February 6, 2008
  10. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998;68:899–917
  11. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals (Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research). Hypertension. 2005;45:142–161
  12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  13. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  14. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  15. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  16. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  17. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52:1331–1338
  18. Tselepis AD, Chapman JM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57–68
  19. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–2138
  20. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923–931
  21. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155
  22. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary artery events by c-reactive protein in apparently healthy middle aged men from the general population. Circulation. 2004;110:1903–1908
  23. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190:388–396
  24. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–2529
  25. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation (Association with early coronary atherosclerosis and endothelial dysfunction in humans). Circulation. 2007;115:2715–2721
  26. Miller K, Eke PI, Schoua-Glusberg A. Cognitive evaluation of self-report questions for surveillance of periodontitis. J Periodontol. 2007;78:1455–1462

 This study was funded by a Research Project Award to Dr. Mosca (R01 HL 075101-01A1) from the National Institutes of Health, Bethesda, Maryland, and supported in part by the Clinical and Translational Science Award Center at Columbia University Medical Center, New York, New York, and a Research Career Award to Dr. Mosca (K24 HL076346-01A1) from the National Institutes of Health.

PII: S0002-9149(08)01272-1

doi: 10.1016/j.amjcard.2008.07.047

American Journal of Cardiology
Volume 102, Issue 11 , Pages 1509-1513 , 1 December 2008

Article Tools